The Trojan Horse Strategy How Vitamin B12 Could Help Sneak Cancer Treatments Into the Brain
Brain cancer treatment has always run into the same wall — literally. The blood-brain barrier, a tightly filtered layer of blood vessels that protects the brain from toxins, bacteria, and infection, also blocks the vast majority of cancer drugs from ever reaching a tumor. Researchers estimate it turns away as much as 98% of potential brain cancer medications, which is part of why glioblastoma multiforme — the most common and aggressive primary brain cancer in adults — remains so difficult to treat. Even with surgery, radiation, and chemotherapy, most patients survive less than 15 months after diagnosis.
A newly published study in the journal Oncoscience is testing a different way in: instead of fighting the barrier, use the tumor’s own hunger against it.
Why Cancer Cells Crave B12
Glioblastoma cells divide rapidly, and that rapid division comes with a heavy demand for the raw materials needed to build new DNA — including vitamin B12, also known as cobalamin. To pull in more of it, these tumor cells display unusually high numbers of a surface receptor called CD320, which normally helps cells absorb B12 from the bloodstream. Healthy brain cells have far fewer of these receptors, which makes B12 uptake a promising way to tell the difference between tumor tissue and everything around it.
Researchers led by Dr. Joseph A. Bauer of the Cleveland Clinic Foundation’s Taussig Cancer Center and Nitric Oxide Services, LLC, built on that idea by engineering a modified B12 molecule called nitrosylcobalamin, or NO-Cbl, designed to carry nitric oxide — a compound with known cancer-killing properties — directly into tumor cells that are, in effect, mistaking it for food.
What the Study Found
The research combined lab testing across a panel of 60 human tumor cell lines with pharmacokinetic and tissue studies in glioblastoma-bearing rats. A few findings stood out:
- It crossed the barrier. After being given systemically, NO-Cbl successfully crossed the blood-brain barrier in the animal models — something most standard chemotherapies struggle to do consistently.
- It stuck around where it mattered. Nitrate levels (a marker of the nitric oxide payload) in tumor tissue peaked shortly after treatment and stayed elevated for at least 24 hours, while levels in healthy tissue cleared out much faster — suggesting the compound concentrates in the tumor rather than spreading evenly through the brain.
- It performed better in combination. When paired with existing glioblastoma treatments like temozolomide and TRAIL, NO-Cbl produced a stronger antitumor effect in human glioma cell lines than either treatment alone.
An Important Caveat
None of this means a bottle of vitamin B12 from the pharmacy has anticancer properties. The compound in this study is a laboratory-engineered version of B12, chemically modified to carry a therapeutic payload that ordinary dietary B12 doesn’t contain. Regular B12 supplements are absorbed by healthy and cancerous cells alike and have no demonstrated effect on tumor growth. Researchers are also careful to note that this work is still in the preclinical stage — it has been tested in cell lines and in rats, not yet in human patients, and there’s a long road of safety and dosing trials ahead before anyone would know whether it works in people.
Why Researchers Are Excited Anyway
What makes this approach notable isn’t just the specific drug — it’s the concept. If a modified vitamin can reliably ferry a therapeutic payload past the blood-brain barrier and concentrate it inside a tumor, the same delivery strategy could potentially be adapted to carry other therapies, not just nitric oxide. That’s a meaningful proof of concept for a field that has struggled for decades to get treatments into the brain at all, let alone selectively.
Glioblastoma remains one of the hardest cancers to treat, and no single study changes that overnight. But research like this — turning a tumor’s own metabolic appetite into a delivery mechanism — represents the kind of incremental, mechanism-first progress that has, in other cancers, eventually led to real clinical breakthroughs. For now, the next steps are further animal safety studies and, if those hold up, the beginning of the long path toward human trials.
Photo by Marek Pavlík on Unsplash
About Wellcore Weekly: Wellcore Weekly covers health, wellness, nutrition, sleep, fitness, and medical research with timely, easy-to-understand updates for everyday readers.
